430 related articles for article (PubMed ID: 34283056)
1. Chromatin and Epigenetic Dysregulation of Prostate Cancer Development, Progression, and Therapeutic Response.
Kukkonen K; Taavitsainen S; Huhtala L; Uusi-Makela J; Granberg KJ; Nykter M; Urbanucci A
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34283056
[TBL] [Abstract][Full Text] [Related]
2. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution.
Imamura J; Ganguly S; Muskara A; Liao RS; Nguyen JK; Weight C; Wee CE; Gupta S; Mian OY
Front Endocrinol (Lausanne); 2023; 14():1191311. PubMed ID: 37455903
[TBL] [Abstract][Full Text] [Related]
3. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.
Storck WK; May AM; Westbrook TC; Duan Z; Morrissey C; Yates JA; Alumkal JJ
Front Endocrinol (Lausanne); 2022; 13():926585. PubMed ID: 35909568
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Regulation in Prostate Cancer Progression.
Ruggero K; Farran-Matas S; Martinez-Tebar A; Aytes A
Curr Mol Biol Rep; 2018; 4(2):101-115. PubMed ID: 29888169
[TBL] [Abstract][Full Text] [Related]
5. Chromatin reprogramming as an adaptation mechanism in advanced prostate cancer.
Braadland PR; Urbanucci A
Endocr Relat Cancer; 2019 Apr; 26(4):R211-R235. PubMed ID: 30844748
[TBL] [Abstract][Full Text] [Related]
6. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer.
De Velasco MA; Tanaka M; Yamamoto Y; Hatanaka Y; Koike H; Nishio K; Yoshikawa K; Uemura H
Carcinogenesis; 2014 Sep; 35(9):2142-53. PubMed ID: 24986896
[TBL] [Abstract][Full Text] [Related]
8. Beyond Expression: Role of Phosphorylated Residues of EZH2 in Lineage Plasticity in Prostate Cancer.
Nouruzi S; Tabrizian N; Zoubeidi A
Endocrinology; 2023 Feb; 164(4):. PubMed ID: 36718085
[TBL] [Abstract][Full Text] [Related]
9. The epigenetic function of androgen receptor in prostate cancer progression.
Sawada T; Kanemoto Y; Kurokawa T; Kato S
Front Cell Dev Biol; 2023; 11():1083486. PubMed ID: 37025180
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between epigenetics and tumor promoting androgen signaling in prostate cancer.
Singh VK; Kainat KM; Sharma PK
Vitam Horm; 2023; 122():253-282. PubMed ID: 36863797
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic modulations and lineage plasticity in advanced prostate cancer.
Ge R; Wang Z; Montironi R; Jiang Z; Cheng M; Santoni M; Huang K; Massari F; Lu X; Cimadamore A; Lopez-Beltran A; Cheng L
Ann Oncol; 2020 Apr; 31(4):470-479. PubMed ID: 32139297
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic (De)regulation in Prostate Cancer.
Xu C; Zhao S; Cai L
Cancer Treat Res; 2023; 190():321-360. PubMed ID: 38113006
[TBL] [Abstract][Full Text] [Related]
14. Current advances of targeting epigenetic modifications in neuroendocrine prostate cancer.
Cheng WC; Wang HJ
Tzu Chi Med J; 2021; 33(3):224-232. PubMed ID: 34386358
[TBL] [Abstract][Full Text] [Related]
15. Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms.
Verma S; Prajapati KS; Kushwaha PP; Shuaib M; Kumar Singh A; Kumar S; Gupta S
Cancer Drug Resist; 2020; 3(4):742-761. PubMed ID: 35582225
[TBL] [Abstract][Full Text] [Related]
16. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
[TBL] [Abstract][Full Text] [Related]
17. Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy.
Cucchiara V; Yang JC; Mirone V; Gao AC; Rosenfeld MG; Evans CP
Cancers (Basel); 2017 Jan; 9(1):. PubMed ID: 28275218
[TBL] [Abstract][Full Text] [Related]
18. The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity.
Davies A; Zoubeidi A; Beltran H; Selth LA
Cancer Discov; 2023 Aug; 13(8):1771-1788. PubMed ID: 37470668
[TBL] [Abstract][Full Text] [Related]
19. Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation.
Zhang Z; Zhou C; Li X; Barnes SD; Deng S; Hoover E; Chen CC; Lee YS; Zhang Y; Wang C; Metang LA; Wu C; Tirado CR; Johnson NA; Wongvipat J; Navrazhina K; Cao Z; Choi D; Huang CH; Linton E; Chen X; Liang Y; Mason CE; de Stanchina E; Abida W; Lujambio A; Li S; Lowe SW; Mendell JT; Malladi VS; Sawyers CL; Mu P
Cancer Cell; 2020 Apr; 37(4):584-598.e11. PubMed ID: 32220301
[TBL] [Abstract][Full Text] [Related]
20. Lineage plasticity-mediated therapy resistance in prostate cancer.
Blee AM; Huang H
Asian J Androl; 2019; 21(3):241-248. PubMed ID: 29900883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
